# name
Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

# metadata.dc.description.abstract[].value
In this retrospective
                cohort study, we aimed to assess whether introducing
                benznidazole at escalating doses reduces the probability of
                adverse events or treatment discontinuation compared with a
                full-dose scheme. We collected data from patients who had
                chronic " - " infection and underwent treatment from July 2008
                to January 2017 in a referral center in Madrid. Dose was
                adjusted to body weight (5 mg/kg/day), with treatment
                introduction with full dose or escalating dose according to
                local consensus and protocols. Among the 62 patients treated,
                benznidazole was introduced at full dose in 28 patients and on
                escalating dose in the remaining 34. We found no statistical
                differences in the number of adverse events, treatment
                discontinuations, days of treatment, or sociodemographic
                profiles. There is insufficient evidence to support escalating
                dose as a strategy for reducing the adverse effects of
                benznidazole. Further research is needed to evaluate this
                strategy.

# metadata.dc.publisher[].value
The American Society of Tropical Medicine and Hygiene

# metadata.dc.relation.ispartof[].value
American Journal of Tropical Medicine and Hygiene, 2019, vol. 100, num. 6, p. 1477-1481

# metadata.dc.rights[].value
(c) The American Society of Tropical Medicine and Hygiene, 2019

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?